UBS Group AG Sells 282,857 Shares of Viridian Therapeutics, Inc. $VRDN

UBS Group AG cut its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 63.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 164,820 shares of the company’s stock after selling 282,857 shares during the quarter. UBS Group AG owned 0.17% of Viridian Therapeutics worth $5,129,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new position in shares of Viridian Therapeutics during the third quarter worth about $35,000. Bessemer Group Inc. grew its stake in Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after purchasing an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new position in Viridian Therapeutics in the third quarter valued at approximately $52,000. US Bancorp DE grew its stake in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares in the last quarter. Finally, Clearstead Advisors LLC grew its stake in Viridian Therapeutics by 3,868.3% in the third quarter. Clearstead Advisors LLC now owns 5,000 shares of the company’s stock valued at $108,000 after purchasing an additional 4,874 shares in the last quarter.

Insider Activity

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the transaction, the director directly owned 5,090,928 shares in the company, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VRDN shares. Wall Street Zen upgraded Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Wedbush decreased their price target on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Evercore set a $26.00 price target on Viridian Therapeutics in a research note on Friday, May 15th. Truist Financial decreased their price target on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Finally, Stifel Nicolaus set a $39.00 price target on Viridian Therapeutics in a research note on Wednesday, May 13th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.14.

Viridian Therapeutics Stock Performance

VRDN opened at $17.69 on Friday. Viridian Therapeutics, Inc. has a 12-month low of $13.18 and a 12-month high of $34.29. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -5.33 and a beta of 0.82. The business has a 50 day moving average of $19.08 and a 200-day moving average of $26.51. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. During the same period last year, the firm posted ($0.87) earnings per share. The business’s revenue was up 95.8% on a year-over-year basis. On average, equities research analysts expect that Viridian Therapeutics, Inc. will post -3.71 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.